We are advancing a broad pipeline of potentially best-in-class antibodies. Learn more about the programs we are developing below.
STRATEGY
TARGET
PROGRAM
DISCOVERY
IND-ENABLING
CLINICAL
Potential best-in-class mAbsExtended half-life
α4β7
SPY001
TL1A
SPY002
IL-23
SPY003
Novel MOA
SPY004
Rational combinations
α4β7 + TL1A
SPY120
α4β7 + IL-23
SPY130
TL1A + IL-23
SPY230
OUR PUBLICATIONSOTHER REFERENCES
OUR PUBLICATIONS